NurExone Biologic

Company Overview

Snapshot

Founded in January 2020, NurExone Biologic operates with 11–50 employees. The company has raised a total of $9.53 million across 8 funding rounds. In July 2022, NurExone Biologic went public on the TSXV.

Business overview

NurExone Biologic is a Health Tech & Life Sciences company focused on revolutionizing recovery from nervous system injuries. The company develops a biological extracellular vesicles-based drug platform designed to treat damage in the Central Nervous System (CNS). Its novel approach to spinal cord injury (SCI) treatment utilizes intranasal exosome administration, offering an alternative to existing therapies. NurExone's technology, developed through research at the Technion and Tel Aviv University, involves exosomes loaded with PTEN siRNA to target complete spinal cord lesions, demonstrating significant functional recovery in preclinical studies.

Strategic signal

In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing process. This patent strengthens the company's supply chain readiness, signaling to investors a significant step towards commercialization and solidifying its intellectual property in the rapidly evolving field of regenerative medicine.

Company Intelligence Q&A

What was a significant regulatory milestone for NurExone Biologic?

In October 2023, NurExone Biologic received FDA Orphan-Drug Designation for its ExoPTEN therapy, accelerating its development for acute spinal cord injury treatment.

What recent patent was granted to NurExone Biologic?

In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing, which is expected to strengthen its supply chain readiness.

What progress has NurExone Biologic made in preclinical studies for vision restoration?

In October 2025, NurExone demonstrated reproducible, dose-dependent vision recovery in a preclinical glaucoma model, indicating potential for broader therapeutic applications beyond spinal cord injury.

What strategic partnership did NurExone Biologic secure?

In October 2023, NurExone secured a Eureka Grant for a collaborative partnership aimed at expanding its therapy to chronic spinal cord injury.

What was NurExone Biologic's most recent funding activity?

In September 2025, NurExone Biologic closed a PIPE funding round, which was part of corporate updates that also included an Israel patent grant.